## EBI report

| | |
|---|---|
| type of report | **Current report** |
| number | 19/2013 |
| company | PHARMENA |

**Positive results of bioavailability testing concerning the safety of use of 1-MNA**

With reference to the Company's Strategy for 2012-2015 (published in current report no. 16/2012 of 13th April 2012) and current report no. 10/2013 of 27th February 2013 (which concerned commencing clinical trials of 1-MNA medicinal product), the Management Board of Pharmena S.A. informs that the subsidiary company Cortria Corporation (USA) concluded bioavailability testing of an innovative anti-atherosclerotic medicinal product based on 1-MNA active substance (working name of the product – TRIA-662).

Bioavailability testing determines the time and levels of absorption of medicinal substance into the general circulation of human organism after single administration. The trial consisted in administration of 1-MNA and niacin (an active substance used in currently sold anti-atherosclerotic medicines) in a single 1000 mg dose.

The trial demonstrated that within the 1-MNA group of patients no adverse side effects were found, and that the medicinal product was safe and well tolerated. Additionally, within the 1-MNA group of patients the so-called flushing effect (redness of skin and hot flashes) was not observed. Whereas, within the niacin group of patients, eleven participants (57.9%) experienced flushing. The results of the trial confirmed the previously made assumptions concerning the safety of use of the medicinal product 1-MNA with increased doses.

The Management Board of Pharmena S.A. also informs that the conclusion of pharmacokinetic analysis (bioavailability) is scheduled for the end of May 2013. The Company will inform the public about the conclusion of the pharmacokinetic analysis in a separate report.

The Management Board of PHARMENA S.A. would like to emphasize that the results of bioavailability tests support the safety of use of the medicinal product 1-MNA with increased doses. After obtaining the pharmacokinetic analysis, the Company will estimate the dose of 1-MNA medicinal product for further phase II clinical trials. The obtained results of bioavailability tests enable the Company to conclude drawing up of an application to Health Canada for granting permission to phase II clinical trials of 1-MNA medicinal product. The Company will inform the public about the submitting of the above-mentioned application to Health Canada in a separate report.

The information is made public due to the fact that the conclusion of bioavailability testing of 1-MNA anti-atherosclerotic medicinal product was necessary to carry out phase II of clinical trials of that product. Potential revenue after commercialisation of the anti-atherosclerotic medicinal product may prove to be very beneficial for the financial and economic situation of the Issuer.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

**Representatives of the company:**

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board